Key findings
- FibroBiologics has filed a new USPTO patent application focused on a fibroblast-derived spheroid platform for disc degeneration, cartilage repair, and joint restoration.
FibroBiologics, a spin-out from SpinalCyte, is developing fibroblasts for a variety of indications, including orthopedics, wounds, and neurodegenerative conditions. They say that fibroblasts offer several advantages over stem cell therapies, namely, easier sourcing, better isolation, and more cost-effective culturing. They outline these advantages on their page here.
Now, they’ve submitted a new patent application to the USPTO titled“Spheroids For Cartilage Repair”, which covers a proprietary fibroblast-derived therapy platform for orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration.
The patent covers FibroBiologics’ approach of using fibroblast cells, spheroids (3D clusters of cells), and/or fibroblast-differentiated chondrocyte spheroids (spheroids made from cartilage-like cells) to support structural and functional repair.
What FibroBiologics reports from preclinical studies
FibroBiologics says preclinical studies show fibroblast-based constructs and chondrocyte spheroids:
- integrate with native tissue
- promote extracellular matrix remodeling (changes in the structural protein network that supports cells)
- encourage regeneration in models of disc degeneration and joint degeneration
Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, said: “The disease landscape is changing, and demand for regenerative orthopedic solutions is accelerating. Our platform has the potential to fundamentally change how we address cartilage loss and degenerative joint disease on a global scale. This is exactly the kind of long-term, high-impact opportunity our technology breakthroughs will allow us to pursue.”
More information: fibrobiologics.com
Want to keep up on regenerative medicine? Get the weekly newsletter here.
